Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Research & Development (2019 - 2026)

Biodesix filings provide 8 years of Research & Development readings, the most recent being $3.3 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 14.46% to $3.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $12.4 million, a 19.51% increase, with the full-year FY2025 number at $12.0 million, up 25.55% from a year prior.
  • Research & Development hit $3.3 million in Q1 2026 for Biodesix, up from $2.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.6 million in Q4 2022 to a low of $1.9 million in Q4 2023.
  • Median Research & Development over the past 5 years was $2.9 million (2023), compared with a mean of $2.8 million.
  • Biggest five-year swings in Research & Development: crashed 47.01% in 2023 and later soared 40.69% in 2025.
  • Biodesix's Research & Development stood at $3.6 million in 2022, then crashed by 47.01% to $1.9 million in 2023, then increased by 27.79% to $2.4 million in 2024, then rose by 18.89% to $2.9 million in 2025, then increased by 14.46% to $3.3 million in 2026.
  • The last three reported values for Research & Development were $3.3 million (Q1 2026), $2.9 million (Q4 2025), and $3.0 million (Q3 2025) per Business Quant data.